Antenatal Vitamin D3 Supplementation in Bangladesh: Randomized Controlled Trial (AViDD-2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01126528|
Recruitment Status : Completed
First Posted : May 19, 2010
Last Update Posted : August 17, 2012
This study is a randomized placebo-controlled trial of oral weekly vitamin D3 (cholecalciferol) supplementation during the third trimester of pregnancy among women in Dhaka, Bangladesh. The overall goal of the study is to establish whether there is evidence that improving vitamin D status among pregnant women in Bangladesh will enhance the resistance of the infant offspring to infection.
The aims of the study are to assess the effect of supplementation on 1) maternal and infant vitamin D status (based on blood concentrations of a vitamin D metabolite) and, 2) markers of neonatal immune function.
|Condition or disease||Intervention/treatment||Phase|
|Pregnancy||Dietary Supplement: Vitamin D3 Dietary Supplement: Placebo control||Phase 2|
The primary aims of this study are:
AIM #1 - To assess the effect of weekly antenatal administration of oral vitamin D3 (875 mcg/week = 35,000 IU week ≈ 5,000 IU per day) started in the third trimester (26-29 weeks gestation) on maternal vitamin D status and fetal-neonatal vitamin D status (cord blood), in comparison to a placebo control supplement.
AIM #2 - To demonstrate the maternal and fetal safety of weekly maternal antenatal (second and third-trimester) vitamin D supplementation at a dose of 875 mcg/week by monitoring maternal serum calcium, urinary calcium excretion, cord blood calcium concentration, and newborn clinical parameters.
AIM #3 - To measure the effect of antenatal vitamin D supplementation on selected biomarkers of fetal-neonatal immune function in cord blood: in vitro stimulated cord blood mononuclear cell (CBMC) LL-37 expression, gene expression related to inflammatory and immunoregulatory pathways, Th1/Th2 cytokine secretion, and bactericidal properties.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||160 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||The Effect of Antenatal Vitamin D Supplementation on Maternal-fetal Vitamin D Status and Neonatal Immune Function: a Randomized Controlled Trial in Bangladesh|
|Study Start Date :||August 2010|
|Actual Primary Completion Date :||May 2011|
|Actual Study Completion Date :||May 2012|
Experimental: Vitamin D3
Vitamin D3 (cholecalciferol)
Dietary Supplement: Vitamin D3
35,000 IU per week, started at 26-29 weeks gestation, until delivery.
Other Name: Cholecalciferol; Vigantol Oil
Placebo Comparator: Control
Placebo control group
Dietary Supplement: Placebo control
Miglyol 812, administered weekly from 26-29 weeks gestation until delivery.
- Serum 25-hydroxyvitamin D concentration [ Time Frame: Maternal: during 3rd trimester; Neonatal (cord blood) ]Biomarker of vitamin D status.
- Serum calcium concentration [ Time Frame: Maternal:3rd trimester; Cord blood. ]
- Urine Ca:Cr ration [ Time Frame: Maternal- 3rd trimester ]
- Neonatal immune function [ Time Frame: Cord blood ]Selected markers of innate and adaptive immunity.
- Infant growth [ Time Frame: Postnatal observational follow-up phase ]Infant growth parameters during postnatal follow-up, up to 12 months of age
- Infant and maternal postnatal vitamin D status [ Time Frame: Postnatal observational follow-up phase ]
- Neonatal serum calcium [ Time Frame: 1st week postnatal ]Infant serum calcium during the first week postnatal.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01126528
|International Centre for Diarrheal Disease Research, Bangladesh (ICDDR,B)|
|Principal Investigator:||Abdullah Baqui, MBBS||JHSPH; ICDDR,B|
|Principal Investigator:||Daniel Roth, MD||Johns Hopkins Bloomberg School of Public Health|
|Principal Investigator:||Rubhana Raqib, PhD||International Centre for Diarrhoeal Disease Research, Bangladesh|